{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:52:03Z","timestamp":1790815923495,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.contraception.2007.04.015","type":"journal-article","created":{"date-parts":[[2007,6,23]],"date-time":"2007-06-23T11:08:37Z","timestamp":1182596917000},"page":"117-125","source":"Crossref","is-referenced-by-count":19,"title":["Safety, tolerance and acceptability of the Invisible Condom\u00ae and its vaginal applicator in healthy women and their male sexual partners"],"prefix":"10.1016","volume":"76","author":[{"given":"Sylvie","family":"Trottier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabeea F.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"D\u00e9sormeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Drouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Vezina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Guilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"M\u00e2sse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel G.","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2007.04.015_bib1","author":"WHO"},{"key":"10.1016\/j.contraception.2007.04.015_bib2","author":"WHO"},{"key":"10.1016\/j.contraception.2007.04.015_bib3","series-title":"HIV impact\u2015a closing the gap newsletter of minority health, US Department of Health and Human Services","first-page":"1","article-title":"The toll of HIV\/AIDS on minority women","author":"Lee","year":"2000"},{"key":"10.1016\/j.contraception.2007.04.015_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1089\/108729102760330263","article-title":"Microbicides 2002: An update","volume":"16","author":"Johnston","year":"2002","journal-title":"AIDS Patient Care and STDs"},{"key":"10.1016\/j.contraception.2007.04.015_bib5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00007435-200108000-00012","article-title":"Thermoreversible gel as a candidate barrier to prevent the transmission of HIV-1 and herpes simplex virus type 2","volume":"28","author":"Piret","year":"2001","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.contraception.2007.04.015_bib6","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.45.6.1671-1681.2001","article-title":"Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases","volume":"45","author":"Roy","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.contraception.2007.04.015_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00007435-199903000-00009","article-title":"Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9","volume":"26","author":"Gagne","year":"1999","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.contraception.2007.04.015_bib8","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1128\/AAC.45.8.2229-2237.2001","article-title":"Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment","volume":"45","author":"Bestman-Smith","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.contraception.2007.04.015_bib9","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.46.9.2933-2942.2002","article-title":"Comparative study of mechanisms of herpes simplex virus inactivation by sodium lauryl sulfate and n-lauroylsarcosine","volume":"46","author":"Piret","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.contraception.2007.04.015_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/AAC.43.2.314","article-title":"A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses","volume":"43","author":"Howett","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.contraception.2007.04.015_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1095\/biolreprod.102.014043","article-title":"Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device","volume":"59","author":"Haineault","year":"2003","journal-title":"Biol Reprod"},{"key":"10.1016\/j.contraception.2007.04.015_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/JCM.29.2.297-301.1991","article-title":"Reliability of diagnosis bacterial vaginosis is improved by a standardized method of Gram stain interpretation","volume":"29","author":"Nugent","year":"1991","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.contraception.2007.04.015_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/01485018208987042","article-title":"A simple assay for human sperm agglutination antibodies","volume":"8","author":"Renton","year":"1982","journal-title":"Arch Androl"},{"key":"10.1016\/j.contraception.2007.04.015_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0002-9343(83)91112-9","article-title":"Non-specific vaginitis","volume":"74","author":"Amsel","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.contraception.2007.04.015_bib15","unstructured":"World Health Organization (WHO) Contraceptive Research and Development Program (CONRAD). Manual for the standardisation of colposcopy for the evaluation of vaginal products. Update 2004, manual WHO\/RHR\/04.2; CONRAD\/2004.1."},{"key":"10.1016\/j.contraception.2007.04.015_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00006250-199203000-00003","article-title":"The Bethesda classification for squamous intraepithelial lesions: histologic, cytologic and viral correlates","volume":"79","author":"Tabbara","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2007.04.015_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0010-7824(00)00155-4","article-title":"Effects of oral contraceptive pill use on vaginal flora and vaginal epithelium","volume":"62","author":"Eschenbach","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2007.04.015_bib18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1086\/315267","article-title":"Effects of contraceptive method on the vaginal microflora: a perspective evaluation","volume":"181","author":"Gupta","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.contraception.2007.04.015_bib19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0140-6736(97)04240-2","article-title":"Hormonal contraception, vitamin A deficiency and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina","volume":"350","author":"Mostad","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2007.04.015_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jps.20752","article-title":"Temperature and pH sensitive smart hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles","volume":"96(3)","author":"Gupta","year":"2007","journal-title":"J Pharmaceutical Sci"},{"key":"10.1016\/j.contraception.2007.04.015_bib21","first-page":"262","article-title":"Adhesion of poloxamer 407 formulations on dog ileal segments in vitro","volume":"37","author":"Juhasz","year":"1991","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.contraception.2007.04.015_bib22","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/01.aids.0000226950.72223.5f","article-title":"Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women","volume":"20","author":"El-Sadr","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2007.04.015_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.aids.0000210608.70762.c3","article-title":"HPTN 050 Protocol Team. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women","volume":"20","author":"Mayer","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2007.04.015_bib24","article-title":"Safety and tolerance of PRO 2000 gel, a candidate vaginal microbicide, in different populations","author":"Lacey","year":"2002"},{"key":"10.1016\/j.contraception.2007.04.015_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/318496","article-title":"Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States","volume":"32","author":"Mayer","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.contraception.2007.04.015_bib26","article-title":"A randomized, placebo-controlled, double-blind expanded safety trial of Carraguard microbicide gel in South Africa: signs and symptoms of genital irritation","author":"Coetzee","year":"2002"},{"key":"10.1016\/j.contraception.2007.04.015_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-6405-3-4","article-title":"HIV Prevention Trial Network (HPTN) 047 Protocol Team. Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune India","volume":"3","author":"Joshi","year":"2006","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.contraception.2007.04.015_bib28","article-title":"Phase I clinical trial to evaluate the safety, tolerance and acceptability of the Invisible Condom when applied intravaginally to healthy female subjects","author":"Trottier","year":"2002"},{"key":"10.1016\/j.contraception.2007.04.015_bib29","series-title":"\u201cMicrobicides 2002\u201d meeting. Antwerp, Belgium","article-title":"Phase I clinical trial to evaluate the safety and acceptability of the Invisible Condom when applied intravaginally to healthy female subjects","author":"Bergeron","year":"2002"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782407001977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782407001977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T08:46:52Z","timestamp":1587631612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782407001977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0010782407001977"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2007.04.015","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}